collagen type IX alpha 1 chainGenealiases: DJ149L1.1.2 · EDM6 · MED · STL4
Q-omics provides the consensus-scored COL9A1 profile across patient tissues and cancer cell-line models. COL9A1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, COL9A1 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, COL9A1 protein abundance shows 18,849 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight HNSC, LIHC, and UCEC as cancer lineages where COL9A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COL9A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COL9A1 survival associations across molecular data types. COL9A1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (12) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COL9A1 RNA expression–survival associations across cancer types. High COL9A1 expression shows unfavorable associations in LGG and DLBC, but favorable associations in HNSC, UCS, CHOL and SCLC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for COL9A1 RNA expression.
This table summarizes COL9A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 8. The strongest signals are observed in LIHC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for COL9A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COL9A1 shows lower tumor expression in KIRC, KIRP and PRAD and higher tumor expression in LIHC, COAD and STAD. The LIHC box plot shows higher COL9A1 RNA expression in tumor versus normal tissue (log2 FC = +0.257, t-test p < 0.001).
This table shows molecular features associated with COL9A1 in patient tissues and cancer cell lines. In patient samples, COL9A1 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, COL9A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and SOFT_TISSUE.
